Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

NewsGuard 100/100 Score
Jul 2 2010

Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis. Rivastigmine tartrate is indicated for treatment of mild to moderate Alzheimer's dementia and mild to moderate Parkinson's disease dementia. Exelon® capsules have annual sales of approximately $130 million in the US.

Source:

Caraco Pharmaceutical Laboratories, Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Lancet Commission predicts sharp increase in global prostate cancer cases
Study highlights growing burden of neurological disorders worldwide
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Common HIV drugs linked to reduced Alzheimer's disease risk
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
New urine-based test improves identification of high-grade prostate cancer
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Supply chain assessment and management, optimizing pharmaceutical supply chains

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients